Pharma Journalist -

Affinia Therapeutics has announced the close of a $40 million Series C financing round to advance development of its lead gene therapy candidate, AFTX-201, for the treatment of BAG3…
Read More...

AstraZeneca and Daiichi Sankyo have announced breakthrough results from the Phase III TROPION-Breast02 trial, showing that their antibody drug conjugate Datroway (datopotamab…
Read More...

Chiesi Group and Arbor Biotechnologies have announced an exclusive global collaboration and licensing agreement to advance the development of innovative gene editing therapies for rare…
Read More...

Neurizon Therapeutics Limited has announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its lead investigational therapy, NUZ-001, a key step…
Read More...

Roche has announced that the U.S. Food and Drug Administration (FDA) has approved the combination of Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and…
Read More...

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a promising anti-microtubule binding region-tau…
Read More...

Taysha Gene Therapies announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TSHA-102, its intrathecally delivered AAV9 gene therapy…
Read More...

Halozyme Therapeutics has announced a definitive agreement to acquire Elektrofi, a biopharmaceutical company known for its breakthrough ultra-high concentration biologics delivery…
Read More...

Takeda Pharmaceutical Company has announced it will discontinue its cell therapy research and development efforts as part of a broader strategic portfolio prioritization. The company…
Read More...

Star Therapeutics has announced the closing of an oversubscribed $125 million Series D financing round to accelerate the development of its pipeline of antibody-based therapies,…
Read More...